MALLINCKRODT ALBUNEX MARKETING TO BEGIN IN EARLY SEPTEMBER
Executive Summary
MALLINCKRODT ALBUNEX MARKETING TO BEGIN IN EARLY SEPTEMBER to an initial group of 10 hospitals following FDA clearance of the product Aug. 5. The approval is the agency's first for an ultrasound contrast imaging agent that can be used for detection in the left side of the heart. Albunex was developed by Molecular Biosystems; Mallinckrodt Medical has marketing rights in North and South America.